Madrigal Pharmaceuticals Deal History & Licensing Activity
Madrigal Pharmaceuticals is a biotech headquartered in US. Over the past three years, Madrigal Pharmaceuticals has been involved in 4 licensing and acquisition transactions, with a primary focus on Oligonucleotides (3 deals). The company currently has 4 active clinical trials, primarily in Metabolic.
Deals (12mo)
7
Active Trials
4
Top Modality
Oligonucleotides
Focus Area
Metabolic
Madrigal Pharmaceuticals Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Madrigal Pharmaceuticals in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| siRNA candidate for MASH | Arrowhead Pharmaceuticals | Oligonucleotides | Unknown | license | May 15, 2026 |
| SYH2086 | Madrigal | Small Molecules | Preclinical | license | Jul 1, 2025 |
Madrigal Pharmaceuticals Pipeline Focus
Therapeutic areas and modalities where Madrigal Pharmaceuticals is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Madrigal Pharmaceuticals Strategic Signals
Key indicators of Madrigal Pharmaceuticals's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Madrigal Pharmaceuticals Clinical Pipeline
Madrigal Pharmaceuticals has 4 active clinical trials across 2 development phases.
1
Phase 2
3
Phase 3
See How Your Asset Matches Madrigal Pharmaceuticals's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Metabolic assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Oligonucleotides Benchmarks
Upfront, milestone, and royalty benchmarks for oligonucleotides deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Madrigal Pharmaceuticals Licensing & Deal Activity
Madrigal Pharmaceuticals is a biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 4 deals over the past three years, Madrigal Pharmaceuticals ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Madrigal Pharmaceuticals include Metabolic (5 deals and trials), Mega Deals (2 deals and trials), Infectious (2 deals and trials), and Gastroenterology (1 deal and trial). In terms of modality, Madrigal Pharmaceuticals has shown particular interest in oligonucleotides, small molecules, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Madrigal Pharmaceuticals and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Madrigal Pharmaceuticals's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.